CORONA REMEDIES
Back to Balance Sheet
|
CORONA REMEDIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Total Non-Current Liabilities | ₹97 Cr | ₹84 Cr | ₹126 Cr | ₹45 Cr |
What is the latest Total Non-Current Liabilities ratio of CORONA REMEDIES ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹97 Cr |
| Mar2025 | ₹84 Cr |
| Mar2024 | ₹126 Cr |
| Mar2023 | ₹45 Cr |
How is Total Non-Current Liabilities of CORONA REMEDIES Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹97 Cr | 15.70 | |
| Mar2025 | ₹84 Cr | -33.38 | |
| Mar2024 | ₹126 Cr | 180.69 | |
| Mar2023 | ₹45 Cr | - | |
Compare Total Non-Current Liabilities of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹12,938.3 Cr | 3.5% | 8.5% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹465,711.0 Cr | -0.8% | 3.5% | 14.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,376.0 Cr | -1% | 7.3% | 7.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,655.0 Cr | -0.9% | 10.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹113,979.0 Cr | -2.1% | -1.8% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,204.7 Cr | -5.8% | -13.2% | -7.7% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 3.5% |
8.5% |
|
| SENSEX | -2.7% |
-0.2% |
-8% |
You may also like the below Video Courses